Start with RegForward Pulse: a focused pilot that helps CMC regulatory consultants find promising biotech opportunities through source-linked briefs. Explore additional tools for regulatory knowledge and submission work as your practice needs them.
A public-source starting point. Your expertise makes the decision.
RegForward Pulse is the first focused pilot. It helps you assess potential clients using public evidence. Other tools address source-linked regulatory questions and CMC drafting as separate, complementary workflows.
Business development intelligence
Spot biotech programs that may need CMC regulatory support. Review a comprehensive, source-linked brief and a tailored outreach draft before deciding whom to contact.
See the RegForward Pulse pilotRegulatory knowledge assistant
Bring together relevant information from authorized guidelines and documents, with links to original sources so you can verify the synthesis.
Explore this pilotCMC submission authoring
AI-assisted tools help consultants prepare and quality-check CMC briefing packages, eCTD sections, and other regulatory documents while they retain control of the deliverable.
Explore this pilotExplore custom development for CMC strategy, agency meeting preparation, and consultant enablement. Additional services for inspections, lifecycle assessment, and due diligence are planned.
Explore all offeringsStart with a focused opportunity brief built from public sources. Regulatory synthesis and CMC drafting are separate pilot conversations. The consultant owns professional decisions and client communication.
For independent consultants and practices seeking a focused way to identify prospective CMC clients.
Find biotechnology companies with public signals of possible CMC support needs, then prepare for an introductory conversation.
RegForward Pulse starts with public information, so an initial pilot does not require client documents. The consultant reviews the evidence, qualifies the opportunity, and leads outreach.
Discuss RegForward Pulse →For CMC consultants and practices exploring guidelines and documents they are authorized to access.
Find relevant passages across sources, compare them, and synthesize the answer with links to the original material.
Verify the cited sources and interpretation. Do not upload employer or client proprietary information without authorization. RegForward Navigate is a knowledge aid.
Discuss RegForward Navigate →For consultants preparing briefing packages, IND and IMPD applications, BLAs, and equivalent global dossiers.
Use AI-assisted drafting and quality-control workflows against authorized source documents, templates, relevant guidelines, health authority expectations, and the consultant's own expertise.
All generated content requires professional review. Outputs are not submission-ready; the consultant remains responsible for the final deliverable.
Discuss RegForward Author →Custom development begins with a needs and feasibility discussion and an agreed scope. Planned concepts are shown to help shape future work and are not yet available.
Tailored AI tools, templates, and document workflows for your practice.
Simulate an agency meeting, practice reviewer-style questions, and examine response gaps ahead of the discussion.
A simulation cannot predict an agency's questions, position, or decision.
Discuss RegForward Rehearse →Organize evidence and identify gaps for CMC regulatory planning.
Define the regulatory strategy and meeting objectives before preparing questions and briefing materials for pre-IND or scientific advice discussions.
RegForward AI does not represent clients before regulatory agencies.
Discuss preparation →A concept for organizing observations, supporting evidence, and draft responses.
A concept for assessing manufacturing changes, technology transfer, and comparability.
A concept for CMC review in investment, licensing, and acquisition work.
A contained first step for consultants: define your focus, review a cited opportunity brief, and decide whether a conversation is worth pursuing.
Share your specialties, target companies, development stages, and preferred engagement types.
Review a comprehensive, source-linked brief and a planned opportunity score that brings together multiple public signals. The consultant checks the evidence before qualifying an opportunity.
Select promising leads and shape a personalized outreach strategy that connects verified signals with your own relevant experience.
Start with public evidence and one practical output: a brief you can assess before choosing whether to pursue the lead. Pilot details are agreed individually.
Read a sample briefThis condensed fictional example shows what a RegForward Pulse opportunity brief could contain, including the evidence behind a lead and a fully written outreach draft. A consultant would receive a comprehensive, source-linked brief with company context, evidence, fit analysis, open questions, and a complete draft to review.
Hypothetical preclinical antibody program · planning for an IND-enabling milestone
What the example shows: An upcoming IND-enabling milestone, a planned manufacturing transfer, and financing directed toward development. Potential CMC support to discuss: control strategy, stability planning, and IND CMC preparation. Outreach would confirm the company's priorities.
The fictional October program update places ABC-101 in IND-enabling studies and describes a planned filing milestone, creating a timely CMC planning window.
Illustrative source: company program page or announcementA planned manufacturing transfer brings process characterization, control strategy, stability planning, and documentation into focus ahead of the filing.
Illustrative source: public manufacturing or partner updateIn this fictional scenario, a financing announcement earmarks resources for ABC-101's IND-enabling work and manufacturing readiness. It signals continued investment in the program.
Illustrative source: company financing announcementThe planned opportunity score would use an internally developed, weighted signal model to prioritize opportunities for consultant review. This fictional example illustrates the type of lead it could surface; the specific signals and weights remain internal.
A targeted engagement could support CMC regulatory strategy, control strategy, stability planning, or preparation of IND CMC content, aligned with BiotechABC's priorities and timeline.
Fictional scenario: BiotechABC's October 2026 update describes ABC-101, a preclinical antibody entering IND-enabling studies, with a manufacturing transfer planned for early 2027. A separate fictional financing announcement says the company plans to fund IND-enabling work and manufacturing readiness. Dr. Maya Chen is a fictional independent consultant with biologics CMC and IND preparation experience. Dr. Alex Reed is the fictional development lead.
Subject: CMC planning for ABC-101's IND-enabling phase
Dear Dr. Reed,
I read BiotechABC's October update on ABC-101. The planned IND-enabling studies and early-2027 manufacturing transfer suggest a useful point to align the process characterization, analytical methods, stability plan, and regulatory narrative.
I advise emerging biologics teams on CMC strategy and IND preparation. In a recent antibody program, I helped the team turn manufacturing-transfer data gaps into a focused IND CMC workplan. If BiotechABC is considering outside support, I would welcome a short discussion about the ABC-101 timeline and whether a targeted gap review would be useful.
I would start with the transfer plan, current control strategy, and evidence needed for the proposed IND. A concise assessment could help your team prioritize work ahead of the filing.
Would a 20-minute conversation next week be useful?
Best,
Dr. Maya Chen
Independent CMC Regulatory Consultant
The names, program update, timeline, and consultant experience in this example are fictional. A real brief and outreach draft would be based on documented sources and the consultant's verified profile; the consultant reviews the completed draft before use.
RegForward Pulse helps surface and assess potential leads. The consultant decides whom to contact, what to say, and what to deliver.
RegForward Navigate supports source-linked regulatory synthesis; RegForward Author helps prepare working submission content.
BiotechABC, ABC-101, the people, and every signal above are fictional. The planned opportunity score will be evaluated and refined during pilots using consultant feedback and observed qualification outcomes. Consultants review the original sources and decide which opportunities warrant outreach.
Regulatory work calls for clear sources, careful interpretation, and professional ownership. The tools are designed around that reality.
Consultants review and approve AI-assisted content before it is used with clients.
Source references help you verify supporting information and return to original materials.
Public facts, professional interpretations, and open questions are kept distinct.
RegForward AI was founded by Stephane Avella, whose experience spans 23 years in biopharmaceutical CMC regulatory work.
That background shapes tools intended to help consultants grow their practices and support client delivery, with expert judgment at the center.
Discuss your workflowTell us what you're working on. A brief, nonconfidential overview is enough to start a conversation about a pilot or tailored package.
Interested in RegForward Pulse? Share your consulting focus and a short, nonconfidential overview. You can also ask about other pilots or custom workflows.
Please do not include confidential client documents, proprietary information, or sensitive personal data.
